Jade Biosciences, Inc. Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net
Jade Biosciences, Inc. (JBIO) had Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net of $0 as of 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Notes › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet · last filed 2026-03-06
- 2025-12-31: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $0.00.
- 2025-09-30: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $0.00.
- 2025-06-30: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $0.00.
| Period end | Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-06 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |